Intrinsiqq
Nymox Pharmaceutical Corporation logo

Nymox Pharmaceutical Corporation Quality Score

NYMXF

Compare
Quality10

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-0.4x

Negative earnings, no valuation support

Not enough quarterly data
for a 1-year trend

Cash Flow Multiple
0/100
-0.7x

Negative FCF, no valuation support

Not enough quarterly data
for a 1-year trend

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution
0/100
14.3%

Heavy dilution above 5%

Capital Structure
100/100
-$74000

Net cash position, no leverage concern

2021
$830000
$391000
2022
$1.00M
$173000
2023
$70000
$0.00
2024
$74000
$0.00
TTM
$74000
$0.00
CashDebt
Customize WeightsPremiumUpgrade

Nymox Pharmaceutical (NYMXF) quality: score, margins and returns

Nymox Pharmaceutical (NYMXF) scores 10/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 3 metrics each scored 0 to 100. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is Nymox Pharmaceutical (NYMXF) a high-quality business?+

Nymox Pharmaceutical scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 3 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Nymox Pharmaceutical's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from NYMXF's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Nymox Pharmaceutical scores well and where it falls behind.

How the market compares: US profitability statistics

Peers

Biotechnology · Pick stocks to compare with NYMXF

CompareIntrinsic value
NEWBRY.XSTONewbury Pharmaceuticals AB
€0.11+0.91%40
HPHA.XETRHeidelberg Pharma AG
€2.01-2.90%10
MEDCL.XPARMedincell SA
€26.70-2.05%40
ZTEKZentek Ltd.
€0.33-0.60%40
XTXXFAdastra Holdings Ltd.
€0.08+0.00%40
XRTXXORTX Therapeutics Inc.
$0.84-5.73%10
VALNValneva SE Sponsored ADR
$5.16-3.82%0
TRIBTrinity Biotech plc Sponsored ADR
$6.24+13.66%10

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing NYMXF

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.